CN1092651A - Cortical hormone compound preparation for external use - Google Patents
Cortical hormone compound preparation for external use Download PDFInfo
- Publication number
- CN1092651A CN1092651A CN 93120481 CN93120481A CN1092651A CN 1092651 A CN1092651 A CN 1092651A CN 93120481 CN93120481 CN 93120481 CN 93120481 A CN93120481 A CN 93120481A CN 1092651 A CN1092651 A CN 1092651A
- Authority
- CN
- China
- Prior art keywords
- acetate
- external
- dehydrocorticosterone
- hydroxy
- exfoliator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention relates to a kind of compound corticoid preparation of external preparation for skin.It is by the external 17-hydroxy-11-dehydrocorticosterone, transdermal enhancer and exfoliator are formed, the external 17-hydroxy-11-dehydrocorticosterone can be hydrocortisone acetate (0.5～1%), Triamcinolone acetonide acetate (0.025～0.2%) etc., and transdermal enhancer can be azacyclo--2-ketone (as a laurocapram 0.3～15%); Dimethyl sulfoxine 15～50%, propylene glycol 15～50% etc., exfoliator is salicylic acid (0.3～6%); Make solution, Emulsion, ointment, aerosol, gel, liposome by the difference that adds organic solvent, substrate and adjuvant.This product has improved transdermal absorption factor and has strengthened antiinflammatory action, thereby improves clinical efficacy, reduces cost.
Description
The present invention relates to a kind of compound corticoid preparation of external preparation for skin.
The present cortical hormone compound preparation for external use of using, generally be that 17-hydroxy-11-dehydrocorticosterone is dissolved in some organic solvents such as the ethanol, perhaps with mixings such as ointment base such as vaseline, sometimes in preparation, add antibiotic and antifungal agent, compound preparation is had also have antibiotic, antifungic action outside the antiinflammatory action, but because the barrier action of keratodermatitis, the Transdermal absorption of such preparation of Chinese medicine is affected, thereby the drug level minimizing of arrival site of action, this type of external 17-hydroxy-11-dehydrocorticosterone transdermal bioavailability is low.
The object of the present invention is to provide a kind of transdermal absorption factor height, cortical hormone compound preparation for external use that curative effect is high.
The present invention is by the external 17-hydroxy-11-dehydrocorticosterone, transdermal enhancer and exfoliator are formed, the external 17-hydroxy-11-dehydrocorticosterone can be hydrocortisone acetate (0.5～1%), hydroprednisone acetate (prednisolone) (0.05～0.2%), dexamethasone acetate (0.05～0.3%), dexamethasone pivalate (0.03～0.2%), acetic acid Beta-corlan (0.03～0.2%), betamethasone valerate (0.03～0.2%), Triamcinolone acetonide acetate (0.025～0.2%), fluocinonide (0.01～0.2%), halcinonidedcorten (0.025～0.1%), triamcinolone (0.05～0.2%), halcinonidedcorten (0.05～0.1%), dipropionic acid Clobetasol (0.03～0.1%), fludrocortisone acetate (0.05～0.25%); Transdermal enhancer can be that azacyclo--2-ketone is (as Laurel nitrogen
Ketone (0.3～15%), 2-Pyrrolidone class (as N-N-methyl-2-2-pyrrolidone N-0.3～15%), dimethyl sulfoxine 15～50%, urea 3～15%, propylene glycol 15～50%, oleic acid 1～10%, terpenes (as Borneolum Syntheticum 0.3～10%); Exfoliator is salicylic acid (0.3～6%); Make solution, Emulsion, ointment (Sorbidon Hydrate, oil-in-water ointment), aerosol, gel, liposome by the difference that adds organic solvent, substrate and adjuvant.
Below in conjunction with embodiment the present invention is described in detail.
Embodiment one: hydrocortisone acetate 10g, salicylic acid 30g, Laurel nitrogen
Ketone 20ml, ointment base add to 1000g, abundant grinding, mixing.
Embodiment two: Triamcinolone acetonide acetate 1g, salicylic acid 20g, Laurel nitrogen
Ketone 20ml, propylene glycol 300ml, ethanol add to 1000ml, dissolving.
Embodiment three: Triamcinolone acetonide acetate 1g, salicylic acid 30g, Laurel nitrogen
Ketone 50ml, ointment base adds to 1000g, the grinding mixing.
Embodiment four: halcinonidedcorten 1g, salicylic acid 10g, Laurel nitrogen
Ketone 10ml, ointment base adds to 1000ml, the grinding mixing.
Embodiment five: halcinonidedcorten 1g, salicylic acid 30g, dimethyl sulfoxine 500ml, ethanol adds to 1000ml.
Embodiment six: dipropionic acid Clobetasol 0.5g, salicylic acid 30g, Borneolum Syntheticum 20g, ointment base adds to 1000g, fully grinds mixing.
This product is because of containing transdermal enhancer, external 17-hydroxy-11-dehydrocorticosterone, salicylic acid, antibiotic transdermal absorption factor (table 1,2,3) have been improved, owing to contain salicylic acid, make this product have exfoliation effect (table 4), salicylic acid has strengthened the antiinflammatory action (table 5) of external 17-hydroxy-11-dehydrocorticosterone as NSAID (non-steroidal anti-inflammatory drug), thereby can improve clinical efficacy, reduce cost.
Table 1.
Laurel nitrogen
Ketone increases the contraction of Triamcinolone acetonide acetate to normal person's forearm inside skin blood vessel
Palor reaction score value
The drug test number (X ± SD)
1 * 10
-5Triamcinolone acetonide acetate ethanol liquid 13 19 ± 4.4
Add 2% Laurel nitrogen chlorine
Ketone
1 * 10
-5Triamcinolone acetonide acetate ethanol liquid 13 29 ± 3.2
※
※With 1 * 10
-5Triamcinolone acetonide acetate ethanol liquor ratio.P＜0.05
Table 2. Laurel nitrogen
Ketone is in the influence of nude mice isolated skin to the salicylic acid transdermal absorption factor
Drug study skin is counted transdermal percentage rate (12h) (% X ± SD)
2% salicylic acid alcoholic solution 7 14 ± 2.1
Add 2% Laurel nitrogen
Ketone
2% salicylic acid alcoholic solution 7 25 ± 3.8
※
※Compare with 2% salicylic acid alcoholic solution.P＜0.01
Table 3. Laurel nitrogen
Ketone is in the influence of nude mice isolated skin to the rifampicin transdermal absorption factor
Drug study number of times transdermal percentage rate (12h) (% X ± SD)
0.5% rifampicin alcoholic solution 20 4.2 ± 1.6
Add 2% Laurel nitrogen
Ketone
0.5% rifampicin alcoholic solution 20 17.1 ± 3.8
※
※Compare with 0.5% rifampicin alcoholic solution.P＜0.01
Table 4. saligenin in compound recipe Triamcinolone acetonide acetate solution to the exfoliation effect of normal person's forearm inside skin
Pharmaceutical samples is counted keratodermatitis labelling mottle and is disappeared
Required natural law X ± SD (day)
Compound recipe Triamcinolone acetonide acetate solution 8 8.8 ± 0.71
※
(containing 2% salicylic acid)
2% salicylic acid alcoholic solution 8 9.4 ± 0.74
※
Lack salicylic " compound recipe acetic acid 8 14.5 ± 1.20
Triamcinolone acetonide solution "
※Compare with scarce salicylic " compound recipe Triamcinolone acetonide acetate solution ".P＜0.01
Table 5. salicylic acid and Triamcinolone acetonide acetate are worked in coordination with anti-U.V. erythema effect
Medicine number of animals rat skin U.V. erythematous response score value
X±SD
Blank 8 1.0 ± 0
0.1% Triamcinolone acetonide acetate alcoholic solution 8 0.69 ± 0.16
0.1% Triamcinolone acetonide acetate
+ 2% salicylic acid alcoholic solution 8 0.31 ± 0.12
※
※Compare with 0.1% Triamcinolone acetonide acetate alcoholic solution.P＜0.05。
Claims (1)
1, a kind of cortical hormone compound preparation for external use, it is characterized in that it is by the external 17-hydroxy-11-dehydrocorticosterone, transdermal enhancer and exfoliator are formed, the external 17-hydroxy-11-dehydrocorticosterone can be hydrocortisone acetate (0.5～1%), hydroprednisone acetate (prednisolone) (0.05～0.2%), dexamethasone acetate (0.05～0.3%), dexamethasone pivalate (0.03～0.2%), acetic acid Beta-corlan (0.03～0.2%), betamethasone valerate (0.03～0.2%), Triamcinolone acetonide acetate (0.025～0.2%), fluocinonide (0.01～0.2%), halcinonidedcorten (0.025～0.1%), triamcinolone (0.05～0.2%), halcinonidedcorten (0.05～0.1%), dipropionic acid Clobetasol (0.03～0.1%), fludrocortisone acetate (0.05～0.25%); Transdermal enhancer can be that azacyclo--2-ketone is (as Laurel nitrogen
Ketone (0.3～15%), 2-Pyrrolidone class (as N-N-methyl-2-2-pyrrolidone N-0.3～15%), dimethyl sulfoxine 15～50%, urea 3～15%, propylene glycol 15～50%, oleic acid 1～10%, terpenes (as Borneolum Syntheticum 0.3～10%); Exfoliator is salicylic acid (0.3～6%); Make solution, Emulsion, ointment (Sorbidon Hydrate, oil-in-water ointment), aerosol, gel, liposome by the difference that adds organic solvent, substrate and adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93120481A CN1042896C (en) | 1993-12-06 | 1993-12-06 | External compound corticoid preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93120481A CN1042896C (en) | 1993-12-06 | 1993-12-06 | External compound corticoid preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1092651A true CN1092651A (en) | 1994-09-28 |
| CN1042896C CN1042896C (en) | 1999-04-14 |
Family
ID=4993329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93120481A Expired - Lifetime CN1042896C (en) | 1993-12-06 | 1993-12-06 | External compound corticoid preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1042896C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687207A (en) * | 2016-02-26 | 2016-06-22 | 江西省皮肤病专科医院 | Ointment for treating dermatitis and eczema and preparation method thereof |
| CN107913279A (en) * | 2017-11-16 | 2018-04-17 | 钟汝华 | A kind of ointment for treating multiple dermatosis |
| CN109602728A (en) * | 2019-01-18 | 2019-04-12 | 江苏福锌雨医药科技有限公司 | A kind of fludrocortisone acetate oral quick-dissolving film preparation and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8706027A1 (en) * | 1986-03-24 | 1987-05-16 | Belda Galiana Manuel F | Topical pharmaceutical compositions for treating vitiligo |
-
1993
- 1993-12-06 CN CN93120481A patent/CN1042896C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687207A (en) * | 2016-02-26 | 2016-06-22 | 江西省皮肤病专科医院 | Ointment for treating dermatitis and eczema and preparation method thereof |
| CN105687207B (en) * | 2016-02-26 | 2018-04-10 | 江西省皮肤病专科医院 | A kind of paste for being used for dermatitis, eczema and preparation method thereof |
| CN107913279A (en) * | 2017-11-16 | 2018-04-17 | 钟汝华 | A kind of ointment for treating multiple dermatosis |
| CN109602728A (en) * | 2019-01-18 | 2019-04-12 | 江苏福锌雨医药科技有限公司 | A kind of fludrocortisone acetate oral quick-dissolving film preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1042896C (en) | 1999-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010149980A2 (en) | Topical formulation containing a tetracycline and a method of treating skin infections using the same | |
| RU2238734C2 (en) | Pharmaceutical composition | |
| DE60315939T2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING AN ANDROGEN | |
| CN1155386C (en) | Nailpolish having function of resisting psoriasis | |
| CN1649603A (en) | Aqueous compositions containing metronidazole | |
| WO1987004346A1 (en) | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases | |
| DE4303214A1 (en) | Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones | |
| JPH0316927B2 (en) | ||
| JPH0336827B2 (en) | ||
| EP0248885B1 (en) | Transdermal delivery of drugs | |
| CN1092651A (en) | Cortical hormone compound preparation for external use | |
| FR2491333A1 (en) | TOPICALLY ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-INFLAMMATORY STEROIDS | |
| Sparreboom et al. | Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography | |
| US3886268A (en) | Iodophor-steroid compound pharmaceutical compositions | |
| CN1065010A (en) | The compositions of steroid | |
| JPS63253022A (en) | Baclofen pharmaceutical for external use | |
| Campbell et al. | Stability of amiodarone hydrochloride in admixtures with other injectable drugs | |
| CN1727325A (en) | Compound of butenafine hydrochloride, preparation method, and application as medication for restraining and killing fungus | |
| JPS6013711A (en) | Penetrative local medicine composition containing corticosteroid | |
| DE2504615A1 (en) | METHOD OF PREPARING A BASE FOR TOPIC ACTIVE STEROIDS | |
| CN1090173A (en) | A kind of prescription and preparation thereof that promotes that drug transdermal absorbs | |
| CN110845384B (en) | Dissociation method of titanium complex drug and application thereof | |
| US3789121A (en) | 17{60 ,21-orthobutyrates of 6{60 , 9{60 -difluoro-hydrocortisone and 6{60 , 9{60 -difluoroprednisolone, compositions containing same and the use thereof as anti-inflammatory agents | |
| Bodor et al. | Enhanced activity of topical hydrocortisone by competitive binding of corticosteroid-binding globulin | |
| JPH06271468A (en) | Solvent for a steroid and liquid medicine for external use, containing a steroid as main component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20131206 Granted publication date: 19990414 |